CoronaryAtlas logo
CoronaryAtlas
Secretory phospholipase A2
Pathway / Plaque inflammation

Secretory phospholipase A2

protein

Inflammatory phospholipase hydrolyzing lipoprotein phospholipids, generating pro-atherogenic lipid mediators.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationalePro-atherogenic enzyme hydrolyzing lipoprotein phospholipids; plaque inflammation mediator.
Also acts inLipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
33
C — confounder / Type-II
60
A — assay feasibility
68
E — evidence strength
23
T1DI (composite)
6
Specificity differential (R−C)-26.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(5)